Intravenous Iron Use in the Care of Patients with Kidney Disease
- 7 June 2019
- journal article
- editorial
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 14 (10) , 1528-1530
Abstract
Many different IV iron preparations are available worldwide, and these differ in their physicochemical characteristics, biologic actions, and quantity of iron able to be administered at a single sitting. Some of the older IV iron preparations (iron sucrose, iron gluconate) exhibit a more rapid release of iron from the iron-carbohydrate complex, limiting the rate and dose of iron administered. This is not a problem in patients receiving maintenance hemodialysis who have ready vascular access, and are attending a dialysis center several times a week. However, patients not receiving dialysis are usually better off receiving one of the newer IV iron preparations (ferric carboxymaltose, ferumoxytol, or iron isomaltoside 1000), which allow for a larger dose of iron to be administered over a relatively short period of time, at a single sitting.Keywords
This publication has 11 references indexed in Scilit:
- Intravenous Iron in Patients Undergoing Maintenance HemodialysisNew England Journal of Medicine, 2019
- Evaluation of the Reported Rates of Severe Hypersensitivity Reactions Associated with Ferric Carboxymaltose and Iron (III) Isomaltoside 1000 in Europe Based on Data from EudraVigilance and VigiBase™ between 2014 and 2017Drug Safety, 2018
- Randomized trial of intravenous iron-induced hypophosphatemiaJCI Insight, 2018
- Drug‐specific hypophosphatemia and hypersensitivity reactions following different intravenous iron infusionsBritish Journal of Clinical Pharmacology, 2017
- Intravenous Versus Oral Iron Supplementation for the Treatment of Anemia in CKD: An Updated Systematic Review and Meta-analysisAmerican Journal of Kidney Diseases, 2016
- Iron management in chronic kidney disease: conclusions from a “Kidney Disease: Improving Global Outcomes” (KDIGO) Controversies ConferenceKidney International, 2016
- A randomized trial of intravenous and oral iron in chronic kidney diseaseKidney International, 2015
- Ferrous Sulfate Supplementation Causes Significant Gastrointestinal Side-Effects in Adults: A Systematic Review and Meta-AnalysisPLOS ONE, 2015
- FIND-CKD: a randomized trial of intravenous ferric carboxymaltose versus oral iron in patients with chronic kidney disease and iron deficiency anaemiaNephrology Dialysis Transplantation, 2014
- Iron Indices in Chronic Kidney Disease in the National Health and Nutritional Examination Survey 1988–2004Clinical Journal of the American Society of Nephrology, 2009